Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Multiple Sclerosis l: Introduction

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

Myasthenia Gravis ll: Pathophysiology

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...

Autoimmune Disorders

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...

Myasthenia Gravis: Diagnostic Tests

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...

Encephalitis ll: Pathophysiology

Encephalitis ll: Pathophysiology

Encephalitis is inflammation of the brain parenchyma caused by direct viral invasion or immune-mediated mechanisms triggered by infections or tumors. Both processes lead to neuronal injury, disrupted neurotransmission, and diverse neurological symptoms, often with overlapping clinical and pathological features.Autoimmune EncephalitisIn autoimmune encephalitis, antibodies target neuronal antigens on cell surfaces, synapses, or within neurons. A key example is anti-NMDAR encephalitis, which can...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

2019 EULAR points to consider for the assessment of competences in rheumatology specialty training.

Annals of the rheumatic diseases·2020

Same author

Eosinophilia-myalgia syndrome induced by excessive L-tryptophan intake from cashew nuts.

Central European journal of medicine·2020

Same author

Validation of the new classification criteria for systemic lupus erythematosus on a patient cohort from a national referral center: a retrospective study.

Croatian medical journal·2019

Same author

2019 EULAR recommendations for the generic core competences of health professionals in rheumatology.

Annals of the rheumatic diseases·2019

Same author

IL-1 receptor blockade skews inflammation towards Th2 in a mouse model of systemic sclerosis.

The European respiratory journal·2019

Same author

EULAR 'points to consider' for the conduction of workforce requirement studies in rheumatology.

RMD open·2019

Search research articles

Related Experiment Video

Updated: Jun 28, 2026

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

Non-MS autoimmune demyelination.

Nada Cikes¹, Dubravka Bosnic, Mirna Sentic

¹Division of Clinical Immunology and Rheumatology, Department of Medicine, School of Medicine and University Hospital Center Zagreb, Zagreb, Croatia. ncikes@mef.hr

Clinical Neurology and Neurosurgery

|October 22, 2008

Summary

Central nervous system involvement in connective tissue diseases can cause demyelination, mimicking multiple sclerosis (MS). Autoantibody and cerebrospinal fluid analysis aid in differentiating these conditions.

More Related Videos

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis

Published on: December 1, 2023

Related Experiment Videos

Last Updated: Jun 28, 2026

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis

Published on: December 1, 2023

Area of Science:

Neurology
Immunology
Rheumatology

Background:

Connective tissue diseases can affect the central nervous system (CNS), leading to white matter demyelination.
These CNS manifestations can be challenging to distinguish from multiple sclerosis (MS) and other demyelinating disorders like transverse myelitis and optic neuritis.

Purpose of the Study:

To highlight the diagnostic challenges posed by CNS demyelination in connective tissue diseases.
To emphasize the importance of differential diagnosis between autoimmune demyelination and MS.

Main Methods:

Review of clinical presentations of CNS involvement in connective tissue diseases.
Discussion of diagnostic tools including magnetic resonance imaging (MRI) for white matter abnormalities.
Highlighting the role of autoantibody testing and cerebrospinal fluid (CSF) analysis.

Main Results:

Demyelinating lesions in the brain and spinal cord are common in connective tissue diseases such as systemic lupus erythematosus, Behcet's disease, Sjogren's syndrome, and systemic sclerosis.
Acute neurological syndromes, similar to early MS symptoms, can be the initial presentation of CNS involvement in these diseases.
MRI findings of white matter abnormalities can be similar in both MS and non-MS autoimmune demyelination.

Conclusions:

Differentiating CNS demyelination in connective tissue diseases from MS is crucial for appropriate management.
Magnetic resonance imaging is a key diagnostic tool for identifying white matter abnormalities.
Autoantibody profiles and CSF analysis are valuable adjuncts in the differential diagnosis.